Short-course radiation plus immunotherapy and chemo before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have been diagnosed with rectal adenocarcinoma (a common type of rectal cancer).
- Your cancer is locally advanced (stage T3-T4 or N+ M0), meaning it has grown into nearby tissues or lymph nodes but hasn't spread to distant organs.
- You are in good general health (able to carry out daily activities) and have adequate blood counts and organ function.
- You have not had previous treatment with PD-1/PD-L1 or CTLA-4 inhibitors (types of immunotherapy).
- You do not have active autoimmune diseases, uncontrolled infections, or significant heart, lung, or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests whether combining short-course radiation with an immune therapy drug (AK112) plus chemotherapy before surgery is better than radiation alone for locally advanced rectal cancer. It aims to shrink tumors and improve outcomes without needing stronger treatments later.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.